← All organizations
Highest phase reached
Phase 3
First clinical trial
Dec 1, 1998First marketed drug
Sep 25, 2000First NDA
Sep 25, 2000Last known activity
Dec 31, 2022
Acquired by Swedish Orphan Biovitrum → Advent International on Jun 26, 2023
Timeline
1990s
- Jan 1, 1991
CTI BioPharma— Founded
2000s
- Sep 25, 2000
arsenic trioxide— NDA Organization
- Jul 31, 2007
Systems Medicine LLC— Acquired
2010s
- May 1, 2012
S*BIO— Acquired
2020s
- Sep 8, 2021
Advent International— Now
- Feb 28, 2022
pacritinib— Marketing Organization
- Feb 28, 2022
pacritinib— NDA Secondary Org
- Jun 26, 2023
Swedish Orphan Biovitrum— Acquired By
Drugs by trial phase (51 distinct, 77 trials)
Phase 3 (16 own, 1 via acquisition)
Phase 2 (25 own, 3 via acquisition)
Phase 1 (5 own, 1 via acquisition)
Indications
Approved for
Studied for
- Aggression
- Brain Neoplasms
- Breast Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Squamous Cell
- Central Nervous System Neoplasms
- Colorectal Neoplasms
- Glioma
- Graft vs Host Disease
- Head and Neck Neoplasms
- Hepatitis
- Hepatitis A
- Hepatitis, Alcoholic
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
- Leukemia, Myelomonocytic, Acute
- Leukemia, Myelomonocytic, Chronic
- Leukemia, Myelomonocytic, Juvenile
- Liposarcoma
- Liposarcoma, Myxoid
- Lung Neoplasms
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Follicular
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Non-Hodgkin
- Multiple Myeloma
- Myelodysplastic-Myeloproliferative Diseases
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- Neoplasm Metastasis
- Neoplasms
- Neoplasms, Plasma Cell
- Neoplasms, Second Primary
- Nervous System Neoplasms
- Ovarian Neoplasms
- Plasmacytoma
- Polycythemia
- Polycythemia Vera
- Preleukemia
- Primary Myelofibrosis
- Prostatic Neoplasms
- Syndrome
- Thrombocythemia, Essential
- Thrombocytopenia
- Thrombocytosis
Marketed drugs (2)
Subsidiaries (2 direct, 2 total across the full acquisition tree)
Recent trials (50)
- NCT05657613Study directorPhase 1Dec 31, 2022
- NCT05657613Lead sponsorPhase 1Dec 31, 2022
- NCT05552183Study directorPhase 1Nov 30, 2022
- NCT05552183Lead sponsorPhase 1Nov 30, 2022
- NCT04447404Study directorPhase 2Sep 21, 2020
- NCT04404361Lead sponsorPhase 3May 22, 2020
- NCT03645824CollaboratorPhase 2Jun 4, 2018
- NCT03432260CollaboratorPhase 2Apr 18, 2018
- NCT03432260Study directorPhase 2Apr 18, 2018
- NCT04884191Lead sponsorPhase 2Jul 31, 2017
- NCT03165734Lead sponsorPhase 2Jun 15, 2017
- NCT02564536CollaboratorPhase 1Jun 1, 2017
- NCT02891603CollaboratorPhase 1/Phase 2Mar 30, 2017
- NCT02800889Lead sponsorPhase 1Oct 1, 2016
- NCT02323607CollaboratorPhase 1Jan 1, 2016
Details
- Founded
- Seattle, WA, US Jan 1, 1991
- First NDA
- Sep 25, 2000
- Last known activity
- Dec 31, 2022
Designations held
- Orphan drug
- Fast track
- Priority review